These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

369 related items for PubMed ID: 9419975

  • 21.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 22. Compensatory ErbB3/c-Src signaling enhances carcinoma cell survival to ionizing radiation.
    Contessa JN, Abell A, Mikkelsen RB, Valerie K, Schmidt-Ullrich RK.
    Breast Cancer Res Treat; 2006 Jan; 95(1):17-27. PubMed ID: 16267617
    [Abstract] [Full Text] [Related]

  • 23.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 24.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 25. Theanaphthoquinone inhibits fatty acid synthase expression in EGF-stimulated human breast cancer cells via the regulation of EGFR/ErbB-2 signaling.
    Weng MS, Ho CT, Ho YS, Lin JK.
    Toxicol Appl Pharmacol; 2007 Jan 15; 218(2):107-18. PubMed ID: 17182072
    [Abstract] [Full Text] [Related]

  • 26.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 27. ErbB2 and EGFR are downmodulated during the differentiation of 3T3-L1 preadipocytes.
    Pagano E, Calvo JC.
    J Cell Biochem; 2003 Oct 15; 90(3):561-72. PubMed ID: 14523990
    [Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30. Neuregulin-2, a new ligand of ErbB3/ErbB4-receptor tyrosine kinases.
    Carraway KL, Weber JL, Unger MJ, Ledesma J, Yu N, Gassmann M, Lai C.
    Nature; 1997 May 29; 387(6632):512-6. PubMed ID: 9168115
    [Abstract] [Full Text] [Related]

  • 31. Role of the C-terminal linear region of EGF-like growth factors in ErbB specificity.
    van der Woning SP, Venselaar H, van Rotterdam W, Jacobs-Oomen S, van Leeuwen JE, van Zoelen EJ.
    Growth Factors; 2009 Jun 29; 27(3):163-72. PubMed ID: 19384683
    [Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35. Epidermal growth factor induces cell death in the absence of overexpressed epidermal growth factor receptor and ErbB2 in various human cancer cell lines.
    Choi J, Moon SY, Hong JP, Song JY, Oh KT, Lee SW.
    Cancer Invest; 2010 Jun 29; 28(5):505-14. PubMed ID: 20073577
    [Abstract] [Full Text] [Related]

  • 36. Anti-EGFR monoclonal antibodies which act as EGF, TGF alpha, HB-EGF and BTC antagonists block the binding of epiregulin to EGFR-expressing tumours.
    Modjtahedi H, Komurasaki T, Toyoda H, Dean C.
    Int J Cancer; 1998 Jan 19; 75(2):310-6. PubMed ID: 9462724
    [Abstract] [Full Text] [Related]

  • 37. Heregulin-dependent translocation and hyperphosphorylation of ErbB-2.
    Zhou W, Carpenter G.
    Oncogene; 2001 Jun 28; 20(29):3918-20. PubMed ID: 11439355
    [Abstract] [Full Text] [Related]

  • 38. Expression of P185erbB-2, P160erbB-3, P180erbB-4, and heregulin alpha in human normal bronchial epithelial and lung cancer cell lines.
    al Moustafa AE, Alaoui-Jamali M, Paterson J, O'Connor-McCourt M.
    Anticancer Res; 1999 Jun 28; 19(1A):481-6. PubMed ID: 10226586
    [Abstract] [Full Text] [Related]

  • 39. EGFR kinase possesses a broad specificity for ErbB phosphorylation sites, and ligand increases catalytic-centre activity without affecting substrate binding affinity.
    Fan YX, Wong L, Johnson GR.
    Biochem J; 2005 Dec 15; 392(Pt 3):417-23. PubMed ID: 16122376
    [Abstract] [Full Text] [Related]

  • 40.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 19.